Our research focus has been the study of small molecules - thalidomide and its derivatives and the novel proteasome inhibitor (PS341) - as new treatments for multiple myeloma. Under the overall direction and mentorship of Dr. Kenneth Anderson, Dr. Richardson is leading several novel, biologically derived translational efforts in multiple myeloma. These have been focused in the clinical study of new drugs in the phase 1 and phase 2 settings; specifically thalidomide, the thalidomide analog IMiD 3 (also known as CC-5013 or CDC-501), 2-methoxy estradiol (2-ME2), and the first-in-class proteasome inhibitor, PS 341 (also known as MLN-341 or Velcade).
Research in high-dose chemotherapy and transplantation-related toxicities including hepatic veno-occlusive disease (VOD) has resulted in the development of the novel agent defibrotide as a therapy for severe hepatic VOD. This has led to further research in endothelial cell injury during high-dose therapy, related treatment strategies, and the study of vascular damage affecting other organ structures including mucosa.